RESUMEN
Ultraviolet B (UVB) irradiation has been known to cause skin damage, which is associated with oxidative stress, DNA damage, and apoptosis. Echinacoside is a phenylethanoid glycoside isolated from Herba Cistanches, which exhibits strong antioxidant activity. In this study, we evaluate the photoprotective effect of echinacoside on UVB-induced skin damage and explore the potential molecular mechanism. BALB/c mice and HaCaT cells were treated with echinacoside before UVB exposure. Histopathological examination was used to evaluate the skin damage. Cell viability, lactate dehydrogenase (LDH) levels, antioxidant enzyme activities, reactive oxygen species (ROS) generation, DNA damage, and apoptosis were measured as well. Western blot was used to measure the expression of related proteins. The results revealed that pretreatment of echinacoside ameliorated the skin injury; attenuated oxidative stress, DNA damage, and apoptosis caused by UVB exposure; and normalized the protein levels of ATR, p53, PIAS3, hnRNP K, PARP, and XPA. To summarize, echinacoside is beneficial in the prevention of UVB-induced DNA damage and apoptosis of the skin in vivo and in vitro.
Asunto(s)
Apoptosis/efectos de los fármacos , Daño del ADN/efectos de los fármacos , Glicósidos/farmacología , Estrés Oxidativo/efectos de los fármacos , Piel/efectos de los fármacos , Rayos Ultravioleta , 8-Hidroxi-2'-Desoxicoguanosina , Animales , Antioxidantes/metabolismo , Proteínas de la Ataxia Telangiectasia Mutada/metabolismo , Línea Celular , Supervivencia Celular/efectos de los fármacos , Fragmentación del ADN/efectos de los fármacos , Fragmentación del ADN/efectos de la radiación , Desoxiguanosina/análogos & derivados , Desoxiguanosina/análisis , Humanos , Queratinocitos/citología , Queratinocitos/efectos de los fármacos , Queratinocitos/metabolismo , L-Lactato Deshidrogenasa/metabolismo , Ratones , Ratones Endogámicos BALB C , Oxidorreductasas/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Piel/metabolismo , Piel/efectos de la radiaciónRESUMEN
OBJECTIVE: Zaltoprofen, a propionic acid derivative of nonsteroidal anti-inflammatory drug (NSAID), has powerful anti-inflammatory and analgesic effects on inflammatory pain. This study was undertaken to investigate the effect of food on the pharmacokinetic parameters of zaltoprofen capsule (trial preparation, T) and tablet (reference preparation, R), and to assess the relative bioequivalence of two zaltoprofen preparations. MATERIALS AND METHODS: In this open-label, randomized, crossover, two-state, four-period study, 24 healthy Chinese volunteers were randomized to receive a single oral dose of zaltoprofen capsule/tablet (80 mg) under fasting and fed state. Plasma samples were obtained for 24 hours and measured by a developed LC-MS/MS method. Pharmacokinetic parameters were calculated using noncompartmental analysis. Safety and tolerability were assessed throughout the study. RESULTS: 24 healthy participants received two zaltoprofen preparations. For zaltoprofen capsule and tablet, coadministration of high-fat food significantly decreased Cmax by 23 and 22%, respectively; tmax was prolonged by 0.7 hours and 0.8 hours, while the AUClast (for T, geometric mean ratio (GMR): 101.81%, 90% confidence interval (CI): 94.71 - 108.14%; for R, GMR: 101.02%, 90% CI: 93.78 - 107.12%) was not significantly affect by the food. Under fasting or fed condition, the 90% CI of T/R ratios of the geometric means for the primary pharmacokinetic parameters AUC and Cmax were within the acceptance range of 80 - 125%. CONCLUSION: These data suggest that the absorption of zaltoprofen is delayed by high-fat-food administration while total exposure is not affected. The two zaltoprofen preparations (capsule and tablet) are bioequivalent under fasting and fed state.â©.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacocinética , Benzopiranos/farmacocinética , Interacciones Alimento-Droga , Propionatos/farmacocinética , Adulto , Área Bajo la Curva , Estudios Cruzados , Humanos , Masculino , Equivalencia Terapéutica , Adulto JovenRESUMEN
In this study, a novel adamantyl nitroxide derivative was synthesized and its antitumor activities in vitro and in vivo were investigated. The adamantyl nitroxide derivative 4 displayed a potent anticancer activity against all the tested human hepatoma cells, especially with IC50 of 68.1 µM in Bel-7404 cells, compared to the positive control 5-FU (IC50=607.7 µM). The significant inhibition of cell growth was also observed in xenograft mouse model, with low toxicity. Compound 4 suppressed the cell migration and invasion, induced the G2/M phase arrest. Further mechanistic studies revealed that compound 4 induced cell death, which was accompanied with damaging mitochondria, increasing the generation of intracellular reactive oxygen species, cleavages of caspase-9 and caspase-3, as well as activations of Bax and Bcl-2. These results confirmed that adamantyl nitroxide derivative exhibited selective antitumor activities via mitochondrial apoptosis pathway in Bel-7404 cells, and would be a potential anticancer agent for liver cancer.
RESUMEN
OBJECTIVE: Renal fibrosis is the common pathological foundation of many chronic kidney diseases (CKDs). The aim of this study was to investigate whether Hydroxysafflor yellow A (HSYA) can preserve renal function by inhibiting the progression of renal fibrosis and the potential mechanisms. METHODS: Renal fibrosis was induced by unilateral ureteral obstruction (UUO) performed on 7-week-old C57BL/6 mice. HSYA (10, 50 and 100 mg/kg) were intragastrically administered. Sham group and model group were administered with the same volume of vehicle. Serum and kidney samples were collected 14 days after the UUO surgery. Serum biochemical indicators were measured by automatic biochemical analyzer. Histological changes were evaluated by HE and Masson staining. In vitro, the anti-fibrotic effect of HSYA was tested on human recombinant transforming growth factor-ß1 (TGF-ß1) stimulated HK-2 cells. The protein levels of α-SMA, collagen-I and fibronectin in kidney tissue and HK-2 cells were measured by immunohistochemistry and immunofluorescence. The protein levels of apoptosis-relative and TGF-ß1/Smad3 signaling were detected by western blot. RESULTS: HSYA slowed the development of renal fibrosis both in vivo and in vitro. In UUO rats, renal function index suggested that HSYA treatment decreased the level of serum creatinine (Scr) and blood urea nitrogen (BUN) rose by UUO (P<0.05). HE staining and Masson staining demonstrated that kidney interstitial fibrosis, tubular atrophy, and inflammatory cell infiltration were notably attenuated in the high-dose HSYA group compared with the model group. The expressions of α-SMA, collagen-I and fibronectin were decreased in the UUO kidney and HK-2 cells of the HSYA-treatment group. Moreover, HSYA reduced the apoptotic rate of HK-2 cells stimulated by TGF-ß1. Further study revealed that HSYA regulated the TGF-ß1/Smads signaling pathway both in kidney tissue and HK-2 cells. CONCLUSIONS: These results suggested that HSYA had a protective effect against fibrosis in renal cells, at least partly, through inhibiting TGF-ß1/smad3-mediated Epithelial-mesenchymal transition signaling pathway.
Asunto(s)
Chalcona/análogos & derivados , Transición Epitelial-Mesenquimal/efectos de los fármacos , Riñón/patología , Quinonas/farmacología , Factor de Crecimiento Transformador beta1/farmacología , Animales , Apoptosis/efectos de los fármacos , Nitrógeno de la Urea Sanguínea , Proliferación Celular/efectos de los fármacos , Chalcona/farmacología , Creatinina/sangre , Modelos Animales de Enfermedad , Fibrosis/tratamiento farmacológico , Fibrosis/prevención & control , Riñón/efectos de los fármacos , Enfermedades Renales/tratamiento farmacológico , Masculino , Ratones Endogámicos C57BL , Proteína smad3/metabolismo , Factor de Crecimiento Transformador beta1/metabolismo , Obstrucción Ureteral/patologíaRESUMEN
Oxidative stress plays an important role in the pathogenesis of various liver diseases. Safflower yellow B (SYB) has been reported to protect the brain against damage induced by oxidative stress; however, whether SYB can also protect hepatocytes from oxidative stress remains unknown. In the present study, to determine whether pre-treatment with SYB reduces hydrogen peroxide (H2O2)induced oxidative stress in HepG2 cells, we investigated H2O2-induced oxidative damage to HepG2 cells treated with or without SYB. Cell viability was measured by MTT assay and cytotoxicity was evaluated by lactate dehydrogenase (LDH) assay. The activities of the antioxidant enzymes, glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) were determined using respective kits. Intracellular reactive oxygen species (ROS) accumulation in the HepG2 cells was monitored using the fluorescent marker, 2',7'-dichlorodihydrofluorescein diacetate (H2DCF-DA). Cell apoptosis was evaluated by determining the activity of caspase-3 and by Annexin V/propidium iodide (PI) double staining. Protein expression levels were measured by western blot analysis, and the levels of related cellular kinases were also determined. H2O2 induced pronounced injury to the HepG2 cells, as evidenced by increased levels of malondialdehyde (MDA) and ROS, the decreased activity of SOD and GSH-Px, the increased activitation of caspase-3 and cell apoptosis, and the loss of mitochondrial membrane potential. SYB significantly inhibited the damaging effects of H2O2, indicating that it protected the cells against H2O2-induced oxidative damage. Moreover, pre-treatment with SYB increased the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase 1 (HO-1) and NAD(P)H dehydrogenase, quinone 1 (NQO1) which are peroxiredoxins. SYB also significantly increased the phosphorylation of AKT. However, this inductive effect was blunted in the presence of the AKT inhibitor, LY294002. The findings of our study suggest that the activation of the AKT/Nrf2 pathway is involved in the cytoprotective effects of SYB against oxidative stress. Our findings provide new insight into the cytoprotective effects of SYB and the possible mechanisms underlying these effects. Thus, SYB may prove to be of therapeutic value for the treatment of various liver diseases.
Asunto(s)
Chalcona/análogos & derivados , Factor 2 Relacionado con NF-E2/metabolismo , Chalcona/farmacología , Células Hep G2 , Humanos , Peróxido de Hidrógeno/farmacología , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Oxidación-Reducción/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Superóxido Dismutasa/metabolismoRESUMEN
Rabeprazole sterile powder for injection (RSPI) is a new formulation, compared with rabeprazole enteric coated tablets. The aim of this study was to evaluate the pharmacokinetic properties and bioavailability of RSPI in healthy Chinese volunteers. Pharmacokinetic studies included an ascending single dose of 10, 20, 40 mg, and a multiple doses of 20 mg. A bioavailability study was evaluated following a single dose of 20 mg between RSPI and Pariet® Pharmacokinetic parameters of rabeprazole given in each treatment period were calculated using non-compartmental analysis. In the PK study, after a single intravenous dose of 10, 20, and 40 mg, the main pharmacokinetic parameters for rabeprazole were as follows: Cmax 566.88, 897.23, 2,171.6 ng/mL; AUClast/794.31, 1,122.76, 2,446.85 ng×h/mL, respectively. After multiple doses of 20 mg, the main pharmacokinetic parameters for rabeprazole were Cmax 991.90 ng/mL, AUClast 1,261.08 ng×h/mL. In the BA study, after a single oral dose of Pariet® 20 mg, the main pharmacokinetic parameters for rabeprazole were Cmax 582.74 ng/mL, AUClast 1,135.5 ng×h/mL. RSPI produced a less-than-proportional increase in exposure with increasing dose in healthy subjects. The accumulation ratio was 1.0, suggesting RSPI displayed no accumulation after repeated administration. The bioavailability of RSPI was increased by ~ 11% as measured by AUClast compared with Pariet® after a single oral administration.
Asunto(s)
Rabeprazol/farmacocinética , Adulto , Área Bajo la Curva , Disponibilidad Biológica , Química Farmacéutica , Femenino , Voluntarios Sanos , Humanos , Inyecciones , Masculino , Polvos , Rabeprazol/administración & dosificaciónRESUMEN
To study urinary excretion properties of rabeprazole and two of its metabolites, i.e. rabeprazole thioether and desmethyl rabeprazole thioether in human urine, a sensitive, selective, accurate and precise method for the quantification of rabeprazole and two of its metabolites using a liquid chromatographic/tandem mass spectrometric method has been developed and validated. Starting with a 200 µL urine aliquot, a general sample preparation was performed using protein precipitation with methanol. Analytes were separated on a Dikma Inspire™ C18 column (150 mm × 2.1mm, 5 µm) using a mixture of methanol and aqueous 10mM ammonium acetate buffer containing 0.05% formic acid (55:45, v/v) as mobile phase. Linearity was obtained over the concentration range of 0.1446-96.38 ng/mL, 0.3198-319.8 ng/mL and 0.05160-82.53 ng/mL for rabeprazole, rabeprazole thioether, desmethyl rabeprazole thioether in human urine, respectively. The fully validated method was applied to a urine excretion study of rabeprazole sodium administered as a 30 min intravenous infusion for the first time. The calculated cumulative urinary recovery just reached 0.04745, 1.272 and 0.1631 of dose within 24h post-dose for rabeprazole, rabeprazole thioether, and desmethyl rabeprazole thioether, respectively, after intravenous infusion administration, indicating that rabeprazole and its two main metabolites undergo substantial non-renal elimination in healthy Chinese volunteers.
Asunto(s)
2-Piridinilmetilsulfinilbencimidazoles/orina , Cromatografía Liquida/métodos , Rabeprazol/orina , Sulfuros/orina , Espectrometría de Masas en Tándem/métodos , 2-Piridinilmetilsulfinilbencimidazoles/metabolismo , 2-Piridinilmetilsulfinilbencimidazoles/farmacocinética , Estabilidad de Medicamentos , Femenino , Humanos , Modelos Lineales , Masculino , Rabeprazol/metabolismo , Rabeprazol/farmacocinética , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Sulfuros/metabolismo , Sulfuros/farmacocinéticaRESUMEN
OBJECTIVE: The objective of this study was to evaluate the pharmacokinetic parameters of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid (HTB), following a single oral dose of 900 mg in healthy subjects under fed and fasting conditions. METHODS: The study participants (n=12) were randomized to receive one 900 mg triflusal capsule in a fasting condition (no food for 12 hours) or a fed condition (after a high-fat meal); after a 2-week washout period, participants received the same dose of triflusal capsule under the converse condition. Pharmacokinetic parameters were calculated using WinNonlin 6.2 software. Safety was evaluated through assessment of adverse events, standard laboratory evaluations, vital signs, and 12-lead electrocardiography. RESULTS: The mean Cmax of triflusal and HTB were 13.96, 110.2 ug/mL for the fasting state and 9.546, 97.15 ug/mL for the fed state, respectively. The AUC0-144 of triflusal and HTB were 19.66, 5,572 hxµg/mL for the fasting state and 22.20, 5,038 hxµg/mL for the fed state, the AUC0-∞ of triflusal and HTB were 19.79, 6,333 hxµg/mL for the fasting state and 22.44, 5,632 hxµg/mL for the fed state, respectively. The results showed that Cmax and AUCs for triflusal were outside the bioequivalency (BE) interval after food intake, but there was no statistically significant change for HTB. CONCLUSION: High-fat food intake may affect the pharmacokinetics of triflusal capsule in healthy subjects.
Asunto(s)
Interacciones Alimento-Droga , Inhibidores de Agregación Plaquetaria/farmacocinética , Salicilatos/farmacocinética , Administración Oral , Adolescente , Adulto , Área Bajo la Curva , Biotransformación , Cápsulas , China , Estudios Cruzados , Grasas de la Dieta/administración & dosificación , Ayuno/sangre , Femenino , Voluntarios Sanos , Humanos , Masculino , Tasa de Depuración Metabólica , Persona de Mediana Edad , Modelos Biológicos , Inhibidores de Agregación Plaquetaria/administración & dosificación , Inhibidores de Agregación Plaquetaria/sangre , Periodo Posprandial , Salicilatos/administración & dosificación , Salicilatos/sangre , Equivalencia Terapéutica , Adulto JovenRESUMEN
A simple and reliable high performance liquid chromatographic (HPLC) method has been developed and validated to quantify cinepazide maleate, a calcium blocker, in rat plasma. Cinepazide maleate and Tinidazole (internal standard) have been extracted by a simple liquid-liquid extraction before injection into chromatographic system. Chromatographic separation was achieved on a reversed phase C18 column with a mobile phase consisted of a water mixture of 10mM potassium dihydrogen phosphate (pH=4.5):methanol (40:60, v/v), pumped at flow rate of 1.0mL/min, and detected at 303nm. The method exhibited a linear range of 0.12-120µg/mL in blank rat plasma, with the lower detection limit of 0.06µg/mL. The method was statistically validated for linearity, accuracy, precision, selectivity and stability following FDA guidelines. The intra- and inter-assay coefficients of variation did not exceed ±15% from the nominal concentration. The accuracy of cinepazide maleate was within ±15% of the theoretical value. The assay has been applied successfully in a pharmacokinetic study of cinepazide maleate after a single intravenous at three doses in rat. And cinepazide maleate injection can improve the bioavailability of cinepazide maleate greatly, and has a dose-dependence profile in rats.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Piperazinas/sangre , Piperazinas/farmacocinética , Animales , Estabilidad de Medicamentos , Límite de Detección , Modelos Lineales , Extracción Líquido-Líquido , Piperazinas/química , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los ResultadosRESUMEN
Multidrug-resistant Acinetobacter baumannii becomes an increasing challenge due to the overuse of antibiotics. Combination therapies are considered as effective options to overcome this matter. The present study was to investigate the synergistic activity of meropenem combined with other antibiotics in vitro and in vivo. Checkerboard assay and time-kill assay were performed to study the combination effects in vitro. For the animal model, a murine sepsis model injected with inoculums intraperitoneally was used. Susceptibility test showed that all the twelve strains in this study were resistant to most of the antibiotics except rifampicin. In combination, meropenem plus rifampicin exhibited synergistic activity against six of twelve strains. In the sepsis model, meropenem monotherapy had no therapeutic effect in this model while it can enhance the activity of rifampicin in both survival rate and bacterial clearance from blood. Moreover, combination therapy significantly reduced plasma IL-6 levels compared with rifampicin monotherapy. Pharmacokinetic analysis of rifampicin was also performed in this study. These data above showed that there was synergistic activity between meropenem and rifampicin against multidrug-resistant Acinetobacter baumannii both in vitro and for experimental model of sepsis. It suggested that combining meropenem with rifampicin may be appropriate in treating multidrug-resistant Acinetobacter baumannii infections.
Asunto(s)
Acinetobacter baumannii/efectos de los fármacos , Modelos Animales de Enfermedad , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Rifampin/administración & dosificación , Sepsis/tratamiento farmacológico , Tienamicinas/administración & dosificación , Infecciones por Acinetobacter/sangre , Infecciones por Acinetobacter/tratamiento farmacológico , Acinetobacter baumannii/fisiología , Animales , Antibacterianos/administración & dosificación , Relación Dosis-Respuesta a Droga , Farmacorresistencia Bacteriana Múltiple/fisiología , Sinergismo Farmacológico , Humanos , Masculino , Meropenem , Ratones , Ratones Endogámicos BALB C , Pruebas de Sensibilidad Microbiana/métodos , Sepsis/sangre , Resultado del TratamientoRESUMEN
PURPOSE: Gastro-esophageal reflux disease is common in patients with type 2 diabetes. A common treatment is the co-administration of proton-pump inhibitors (PPIs) and metformin. To date, however, the effects of co-administration of PPIs, which inhibit organic cation transporter (OCT) activity, on the action of metformin (a well-known substrate of OCTs) have not been clearly demonstrated. METHODS: This was a randomized, double-blind, two-way crossover, placebo-controlled trial. Healthy male volunteers (n = 20) received metformin (single dose 1,000 mg on day 1 and single dose 750 mg on day 2, with a 12-h interval) co-administered with placebo or with lansoprazole (30 mg). Plasma concentrations of metformin were measured up to 24 h after the second dose. The glucose-lowering effects of metformin were evaluated by the oral glucose tolerance test before and after each single dose of metformin within the 2-day period. RESULTS: Lansoprazole increased the mean metformin maximum plasma concentration and area under the plasma concentration-time curve from zero to 24 h after the second dosing by 15 and 17 %, respectively (P < 0.05). Moreover, lansoprazole prolonged the metformin elimination half-life from 3.9 to 4.5 h and decreased its renal clearance by 13 % (P < 0.05). However, lansoprazole had no effect on the maximum glucose level and the area under the serum glucose concentration-time curve of metformin. CONCLUSIONS: Collectively, we found a modest pharmacokinetic drug interaction between lansoprazole and metformin, which suggests that the concomitant use of these drugs should be appropriately monitored. Further studies are warranted to assess changes in metformin pharmacokinetics in patients with diabetes receiving long-term lansoprazole therapy.
Asunto(s)
Antiulcerosos/farmacología , Hipoglucemiantes/farmacocinética , Lansoprazol/farmacología , Metformina/farmacocinética , Proteínas de Transporte de Catión Orgánico/antagonistas & inhibidores , Inhibidores de la Bomba de Protones/farmacología , Adulto , Glucemia/análisis , Estudios Cruzados , Método Doble Ciego , Interacciones Farmacológicas , Prueba de Tolerancia a la Glucosa , Voluntarios Sanos , Humanos , Hipoglucemiantes/sangre , Hipoglucemiantes/farmacología , Hipoglucemiantes/orina , Masculino , Metformina/sangre , Metformina/farmacología , Metformina/orinaRESUMEN
Pivalate-generating prodrugs have been suggested to cause clinically significant hypocarnitinaemia. Tenofovir dipivoxil, a novel ester prodrug of tenofovir, can be used for treatment for hepatitis B and HIV infection and it was necessary to evaluate the effect of its treatment on carnitine homeostasis. We sought to investigate the effect of Class 1 drug tenofovir dipivoxil on endogenous L-carnitine level during a 72-hr test in healthy Chinese volunteers and to establish a suitable dose of L-carnitine nutritional supplement for patients who were administered short-term tenofovir dipivoxil tablets for treatment for hepatitis B and herpes simplex virus infection. Tenofovir dipivoxil was administered in one of eight dosing regimens (single dose 150, 300 and 600 mg, multiple dose 300, 450, and 600 mg, multiple dose 450 (600) mg tenofovir dipivoxil and 0.5 g L-carnitine) to gender-balanced groups of 84 healthy Chinese volunteers. Plasma concentrations of L-carnitine were quantified before, during and after treatment. Plasma L-carnitine concentrations fell during tenofovir dipivoxil dosing. The nadir in L-carnitine concentration was dependent on the dose of tenofovir dipivoxil and it decreased from 6.1 ± 0.6 to 4.4 ± 0.8 µg/ml, 6.1 ± 1.8 to 3.3 ± 1.2 µg/ml, 6.2 ± 0.6 to 2.5 ± 0.5 µg/ml for single doses of 150, 300, 600 mg tenofovir dipivoxil tablets and from 6.0 ± 1.4 to 2.1 ± 1.5 µg/ml, 6.2 ± 0.4 to 0.9 ± 0.5 µg/ml for multiple doses of 450, 600 mg tenofovir dipivoxil tablets, respectively. Short-term administration of tenofovir dipivoxil results in hypocarnitinaemia and increased losses of carnitine in resulting of minor adverse events of decreased food appetite, nausea, abdominal distention and muscle weakness.
Asunto(s)
Adenina/análogos & derivados , Antivirales/farmacología , Carnitina/metabolismo , Homeostasis/efectos de los fármacos , Organofosfonatos/farmacología , Profármacos/farmacología , Adenina/farmacología , Adenina/uso terapéutico , Adulto , Antivirales/uso terapéutico , Carnitina/sangre , Relación Dosis-Respuesta a Droga , Femenino , Hepatitis B/tratamiento farmacológico , Herpes Simple/tratamiento farmacológico , Humanos , Masculino , Organofosfonatos/uso terapéutico , TenofovirRESUMEN
Brazilin is an important constituent of Caesalpinia sappan L., and has several bioactivities. In this study, a rapid and sensitive analytical method based on high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) has been developed for the determination of brazilin in rat plasma, urine, feces and tissues (brain, heart, liver, lung and kidney and spleen). Biological samples were processed with ethyl acetate containing 5% formic acid extraction, and salicylic acid (SA) was chosen as the internal standard (IS). The separation of brazilin was achieved on an Inspire C18 column (4.6mm×150mm, 5µm) with a mobile phase consisting of methanol/5mM ammonium acetate (80:20, v/v). The MS/MS detection was carried out by monitoring the fragmentation of m/z 285.1â163.0 for brazilin and m/z 137.1â93.1 for SA on a triple quadrupole mass spectrometer. The total run time was only 5.0min. The analyte showed good linearity over a wide concentration range (R(2)>0.995) and its lower limit of quantification was 2ng/mL. The accuracy and precision ranged from 97.1 to 103.3% and 1.7 to 9.1%, respectively. Recoveries (78.9-93.8%) and matrix effects (81.0-97.8%) were satisfactory in all the biological matrices examined. Stability studies (86.4-99.8%) showed that brazilin was stable during the assay procedure and long-term storage. The assay was successfully applied to plasma pharmacokinetics, tissue distribution and excretion study of rats. The pharmacokinetic parameters, such as half-life, mean residence time, maximum concentration were determined. These preclinical data of brazilin would be useful for the clinical reference.
Asunto(s)
Benzopiranos/análisis , Benzopiranos/farmacocinética , Cromatografía Líquida de Alta Presión/métodos , Espectrometría de Masas en Tándem/métodos , Animales , Benzopiranos/química , Estabilidad de Medicamentos , Límite de Detección , Modelos Lineales , Masculino , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los Resultados , Distribución TisularRESUMEN
In this study, the authors compared the effects of amlodipine (AML) on the bioavailability of cephalexin (LEX) and cefuroxime axetil (CXM). Twenty-four healthy men were randomized to 4 treatments according to a crossover design with a 14-day washout. After an overnight fast, they were administered orally LEX 500 mg alone, LEX 500 mg 2 hours after oral administration of AML 5 mg, CXM 500 mg alone, and CXM 500 mg 2 hours after oral administration of AML 5 mg. All participants completed the whole study without side effects being observed. Pharmacokinetic data were analyzed by noncompartmental modeling with WinNonlin software. The geometric mean (GM) ratios were 1.38 (90% confidence interval [CI], 1.32-1.45) for the area under the concentration-time curve (AUC) for LEX and 1.27 (1.18-1.36) for the maximum concentration of drug in serum (C(max)) for LEX followed by AML versus alone. In contrast, no significant differences were found in the pharmacokinetic parameters of CXM between treatments (P < .05). They authors conclude that AML possesses an enhancement effect in ß-lactam antibiotic bioavailability (in this case, LEX), and this interaction may be specific to the peptidomimetic ß-lactam antibiotics.
Asunto(s)
Amlodipino/administración & dosificación , Antibacterianos/farmacocinética , Bloqueadores de los Canales de Calcio/administración & dosificación , Cefuroxima/análogos & derivados , Cefalexina/farmacocinética , Adulto , Antibacterianos/administración & dosificación , Antibacterianos/sangre , Disponibilidad Biológica , Cefuroxima/administración & dosificación , Cefuroxima/sangre , Cefuroxima/farmacocinética , Cefalexina/administración & dosificación , Cefalexina/sangre , Estudios Cruzados , Humanos , MasculinoRESUMEN
BACKGROUND AND OBJECTIVE: Tenofovir dipivoxil fumarate (9-[(R)-2-[[bis (pivaloyloxymethoxy) phosphinoyl] methoxy] propyl] adenine fumarate) is a novel ester prodrug of tenofovir. It has been developed as an anti-hepatitis B virus clinical candidate. The purpose of this study was to determine the pharmacokinetic parameters of tenofovir dipivoxil fumarate (test) and the commercially available tenofovir disoproxil fumarate (Viread®, reference). In addition, the bioavailability of tenofovir dipivoxil fumarate was evaluated in healthy male fasted subjects after a single comparatively equivalent dose. METHODS: This single-dose, randomized, two-way, open-label, crossover study was conducted at Xijing Hospital, Xi'an, China. The study drug was administered under fasted conditions. Serial blood samples were obtained over 72 hours after oral administration of each treatment. Bioavailability of the drug was assessed in accordance with the State Food and Drug Administration bioequivalence criteria. RESULTS: Eighteen subjects were enrolled and completed the study, with all study treatments being generally well tolerated. The geometric mean ratios (90% confidence interval [CI]) for maximum plasma concentration (C(max)), area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUC(last)), and area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC(∞)) were 124.49% (90% CI 115.85, 133.79), 122.85% (90% CI 115.55, 130.62), and 122.43% (90% CI 115.71, 129.54), respectively. CONCLUSION: The relative bioavailability of tenofovir dipivoxil was 20% higher compared with tenofovir disoproxil fumarate; this result was consistent with the preclinical data.
Asunto(s)
Adenina/análogos & derivados , Organofosfonatos/farmacocinética , Inhibidores de la Transcriptasa Inversa/farmacocinética , Adenina/administración & dosificación , Adenina/efectos adversos , Adenina/farmacocinética , Administración Oral , Adolescente , Adulto , Área Bajo la Curva , Disponibilidad Biológica , Estudios Cruzados , Hepatitis B/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Organofosfonatos/administración & dosificación , Organofosfonatos/efectos adversos , Ácidos Fosforosos , Profármacos , Inhibidores de la Transcriptasa Inversa/administración & dosificación , Inhibidores de la Transcriptasa Inversa/efectos adversos , Tenofovir , Equivalencia Terapéutica , Adulto JovenRESUMEN
The purpose of this study was to assess the potential inhibitory and inductive effects of felotaxel on cytochrome P450 isozymes in vitro. The inhibitory effects of felotaxel on various CYP isozymes were determined in human liver microsomes. In addition, the ability of felotaxel to induce CYP enzymes in cultured human hepatocytes was evaluated. Results showed that felotaxel did not inhibit CYP1A2-, CYP2C9-, CYP2C19-, CYP2E1-, CYP2D6-, CYP2B6-, CYP2C8-, and mediated activities in human liver microsomes up to a concentration of 100 µM, while the inhibition (<30% inhibition) of CYP3A4 activities was observed at 100 µM felotaxel. In vitro felotaxel did not induce CYP1A2, CYP2C19, or CYP3A4/5 activities in cultured human hepatocytes. In present study, felotaxel has been identified as a potent inhibitor of metabolic activity of CYP3A4. Therefore, clinically relevant pharmacokinetic drug-drug interactions are likely to occur between felotaxel and co-administered substrates of these CYP3A4 isozymes. These findings provided some useful information for safe and effective use of felotaxel in clinical practice.
Asunto(s)
Antineoplásicos/farmacología , Inhibidores Enzimáticos/farmacología , Microsomas Hepáticos/efectos de los fármacos , Taxoides/farmacología , Antineoplásicos/administración & dosificación , Células Cultivadas , Inhibidores Enzimáticos del Citocromo P-450 , Sistema Enzimático del Citocromo P-450/metabolismo , Relación Dosis-Respuesta a Droga , Inducción Enzimática/efectos de los fármacos , Inhibidores Enzimáticos/administración & dosificación , Hepatocitos/efectos de los fármacos , Hepatocitos/enzimología , Humanos , Microsomas Hepáticos/enzimología , Taxoides/administración & dosificaciónRESUMEN
Felotaxel (SHR110008), currently under clinical investigation in phase I trial, is a new effective taxane with greater anticancer activity and less toxicity than docetaxel. Pharmacokinetic studies in animal models are the important components in clinical development of this agent. In this study, a rapid and sensitive analytical method based on high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) has been developed for the determination of felotaxel in tumor-bearing mice plasma, urine, feces and tissues (brain, heart, liver, lung and kidney and tumor). For all matrices, sample preparation involved liquid-liquid extraction with ethyl acetate. Calibration curves (1/x² weighted) offered satisfactory linearity (r² ≥ 0.995) within the test range. The lower limit of quantitation (LLOQ) for all matrices was 10 ng/ml except that for mouse plasma and brain LLOQ was 1 ng/ml. The accuracy and precision ranged from 86.1 to 107.2% and 1.1 to 9.2%, respectively. Recoveries (73.9-96.1%) and matrix effects (76.4-97.2%) were satisfactory in all the biological matrices examined. Stability studies (85.1-101.5%) showed that felotaxel was stable both during the assay procedure and long-term storage. The assay was successfully applied to plasma pharmacokinetics, tissue distribution and excretion study of mice. The pharmacokinetic parameters, such as half-life, mean residence time, maximum concentration were determined. The preclinical data are useful for the design of clinical trials of felotaxel.
Asunto(s)
Antineoplásicos/farmacocinética , Cromatografía Liquida/métodos , Neoplasias Pulmonares/metabolismo , Espectrometría de Masas en Tándem/métodos , Taxoides/farmacocinética , Animales , Antineoplásicos/análisis , Antineoplásicos/química , Diazepam , Estabilidad de Medicamentos , Neoplasias Pulmonares/tratamiento farmacológico , Masculino , Ratones , Ratones Desnudos , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Taxoides/análisis , Taxoides/química , Distribución Tisular , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Felotaxel (SHR110008), currently under clinical investigation in phase I trial, is a new taxane with potent antitumor effects. The purpose of this research was to evaluate the pharmacokinetic profiles of felotaxel in rats and the protein binding in plasma. Data were collated from several preclinical investigations, where the plasma pharmacokinetics, tissue distribution and excretion of felotaxel were assessed after a single intravenous (i.v.) injection (5 mg/kg) to rats. Samples felotaxel concentration was determined by a LC-MS/MS method. The plasma concentration versus time data was analyzed non-compartmental model. Plasma protein binding was assessed using ultrafiltration. Pharmacokinetic properties of felotaxel were similar to the previous data from the rats. Felotaxel was rapidly distributed to normal tissues, drug concentrations in the tissues tested except the brain were two to eight times higher than those in plasma, but half-lives and mean residence times were similar. The kidneys manifested as the dominant organs with high exposure that might be responsible for elimination of felotaxel. Approximately 0.21% and 0.72% of felotaxel was excreted via the urine and feces within 24 h; 0.25% was excreted into the bile up to 12 h after a single dose. The protein binding ability of felotaxel with concentration 100-5000 ng/mL in the plasma was nearly linear. This study first provided the full absorption, distribution, and excretion characteristics of felotaxel, which would be helpful for its clinical regiment design.
Asunto(s)
Antineoplásicos/farmacocinética , Modelos Biológicos , Taxoides/farmacocinética , Animales , Encéfalo/metabolismo , Cromatografía Liquida , Femenino , Semivida , Riñón/metabolismo , Masculino , Unión Proteica , Ratas , Ratas Sprague-Dawley , Espectrometría de Masas en Tándem , Factores de Tiempo , Distribución TisularRESUMEN
AIMS: To investigate the effect of zinc sulfate on pharmacokinetics of cephalexin when administered concurrently or at strategically spaced dosing times designed to avoid the potential interaction in healthy volunteers. METHODS: In this study, all subjects (n= 12) were randomized to receive the following four treatments, separated by a wash-out period of 7 days: cephalexin 500mg alone, concomitantly with zinc 250mg, 3h after zinc 250mg or 3h before zinc 250mg. RESULTS: All subjects completed the study safely. Zinc supplements administered concurrently with cephalexin significantly decreased the peak serum concentration (C(max) ), area under the plasma concentration-time curve from zero to infinity (AUC(0-∞) ) and the time for which the plasma concentration of the drug remained above the minimal inhibitory concentration of the pathogenic organism (T > MIC) of cephalexin [mean percentage decrease (95% confidence intervals) of 31.05% (22.09-40.01%), 27.40% (18.33-36.47%) and 22.33% (12.51-32.16%), respectively; P < 0.05] compared with administration of cephalexin alone. Also, administration of zinc 3h before cephalexin decreased the C(max) , AUC(0-∞) and T > MIC of the drug compared with administration of cephalexin alone [mean percentage decrease (95% confidence intervals) of 11.48% (3.40-19.55%), 18.12% (9.63-26.60%) and 23.75% (14.30-33.20%), respectively; P < 0.05]. In contrast, the pharmacokinetics of cephalexin was not notably altered by administration of zinc 3h after cephalexin dosing (P > 0.05). CONCLUSIONS: The significant interaction between zinc and cephalexin might affect the clinical outcome of cephalexin therapy. The dosing recommendation is that zinc sulfate can be safely administered 3h after a cephalexin dose.
Asunto(s)
Antibacterianos/farmacocinética , Cefalexina/farmacocinética , Sulfato de Zinc/farmacología , Administración Oral , Adulto , Antibacterianos/administración & dosificación , Disponibilidad Biológica , Cefalexina/administración & dosificación , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Interacciones Farmacológicas , Humanos , Masculino , Sulfato de Zinc/administración & dosificaciónRESUMEN
BACKGROUND: The 1-methyl-4-phenylpyridinium ion (MPP(+)), an inhibitor of mitochondrial complex I, has been widely used as a neurotoxin because it causes a severe Parkinson's disease-like syndrome accompanied by increased levels of intracellular reactive oxygen species (ROS) and apoptotic death. In the present study, we investigated the protective effects of osthole, a coumarin compound extracted from the plant-derived medicine Cnidium monnieri, on MPP(+)-induced cytotoxicity in cultured rat adrenal pheochromocytoma (PC12) cells. METHODS: PC12 cells were treated with MPP(+) 2h after treated with different concentrations of osthole. 24h later, the cell viability, the release of lactate dehydrogenase, the activity of caspase-3 and cytochrome c, the expression ratio of Bax/Bcl-2 and the generation of intracellular ROS were detected. RESULTS: We found that pretreatment with osthole on PC12 cells significantly reduced the loss of cell viability, the release of lactate dehydrogenase, the activity of caspase-3 and cytochrome c, the increase in Bax/Bcl-2 ratio and the generation of intracellular ROS induced by MPP(+). Moreover, our HPLC analysis of cell extracts confirmed that extracellular osthole does penetrate the cell membrane. Thus osthole may function as an intracellular antioxidant to reduce oxidative stress induced by MPP(+). CONCLUSIONS: Therefore, the present study supports the notion that osthole may be a promising neuroprotective agent for the treatment of neurodegenerative disorders such as Parkinson's disease.